These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
990 related articles for article (PubMed ID: 25248588)
1. Hyperprolactinemia and prolactinoma. Romijn JA Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588 [TBL] [Abstract][Full Text] [Related]
2. Hyperprolactinemia and prolactinomas. Mancini T; Casanueva FF; Giustina A Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731 [TBL] [Abstract][Full Text] [Related]
3. Prolactin in men's health and disease. Bolyakov A; Paduch DA Curr Opin Urol; 2011 Nov; 21(6):527-34. PubMed ID: 21941183 [TBL] [Abstract][Full Text] [Related]
4. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629 [TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia: pathophysiology and management. Verhelst J; Abs R Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552 [TBL] [Abstract][Full Text] [Related]
6. [Hyperprolactinemia in the postmenopause: versions and contraversions]. Leshchenko OY Ter Arkh; 2021 Oct; 93(10):1234-1239. PubMed ID: 36286827 [TBL] [Abstract][Full Text] [Related]
13. Update on prolactinomas. Part 2: Treatment and management strategies. Wong A; Eloy JA; Couldwell WT; Liu JK J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714 [TBL] [Abstract][Full Text] [Related]
14. [Some issues in the diagnosis and treatment of hyperprolactinemia]. Jin ZM Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959 [No Abstract] [Full Text] [Related]
15. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787 [TBL] [Abstract][Full Text] [Related]
17. [Current diagnosis and treatment of hyperprolactinemia]. Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213 [TBL] [Abstract][Full Text] [Related]
18. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Hu J; Zheng X; Zhang W; Yang H Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765 [TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management. Pekić S; Medic Stojanoska M; Popovic V Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396 [TBL] [Abstract][Full Text] [Related]
20. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Chanson P; Maiter D Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]